Kineta could receive more than $359 million as a result of the deal.
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta’s existing target therapy into a medicine that treats nerve pain.
“There is a tremendous unmet patient need to develop more effective, safer and nonaddictive therapies for the many people who suffer from chronic pain,” Kineta CEO Shawn Iadonato said in a statement Monday.
The Seattle company will be eligible to receive up to $359 million as part of the deal, in addition to an undisclosed upfront payment. It could also receive royalties on eventual sales of products that result from the deal.
Most Read Business Stories
- Emirates negotiations may deal blow to key Boeing 777X order
- New Airbus leadership steps out in Paris Air Show, talks climate change and trashes Boeing
- First flight of Boeing's new 777X delayed at least until the fall VIEW
- Former tobacco executive is making his mark at Ste. Michelle Wine Estates
- Muilenburg says Boeing brings ‘a tone of humility and learning’ over 737 MAX to Paris Air Show